Key Points
- David Joseph Gaffin, EVP of Alkermes, sold 2,034 shares on May 4 at an average price of $33.20 under a pre-arranged Rule 10b5-1 trading plan, for proceeds of $67,528.80.
- Following the sale he still owns 231,558 shares (a 0.87% reduction), and he executed two similar monthly sales earlier this year (2,034 shares on April 6 at $34.57 and on March 2 at $29.29).
- Alkermes trades in the mid-$30s (50-day SMA $31.44, 200-day SMA $30.95) with a market cap of about $5.68B, and analysts have an average target of roughly $44.29 (consensus "Moderate Buy").
Alkermes plc (NASDAQ:ALKS - Get Free Report) EVP David Joseph Gaffin sold 2,034 shares of the company's stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.20, for a total transaction of $67,528.80. Following the transaction, the executive vice president owned 231,558 shares of the company's stock, valued at approximately $7,687,725.60. This represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Joseph Gaffin also recently made the following trade(s):
- On Monday, April 6th, David Joseph Gaffin sold 2,034 shares of Alkermes stock. The stock was sold at an average price of $34.57, for a total transaction of $70,315.38.
- On Monday, March 2nd, David Joseph Gaffin sold 2,034 shares of Alkermes stock. The stock was sold at an average price of $29.29, for a total transaction of $59,575.86.
Alkermes Price Performance
ALKS stock opened at $34.17 on Tuesday. The company has a 50 day simple moving average of $31.44 and a 200 day simple moving average of $30.95. The stock has a market cap of $5.68 billion, a price-to-earnings ratio of 23.90 and a beta of 0.31. Alkermes plc has a 1 year low of $25.17 and a 1 year high of $36.48.
Alkermes (NASDAQ:ALKS - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported $0.29 earnings per share (EPS) for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The business had revenue of $384.55 million during the quarter. On average, equities research analysts anticipate that Alkermes plc will post -0.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. Baker BROS. Advisors LP lifted its position in shares of Alkermes by 23.7% during the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company's stock valued at $280,143,000 after acquiring an additional 1,920,916 shares during the period. State Street Corp lifted its position in shares of Alkermes by 10.9% during the 4th quarter. State Street Corp now owns 9,472,858 shares of the company's stock valued at $265,051,000 after acquiring an additional 932,507 shares during the period. Renaissance Technologies LLC lifted its position in shares of Alkermes by 6.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,668,028 shares of the company's stock valued at $186,571,000 after acquiring an additional 375,500 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Alkermes by 32.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company's stock valued at $145,064,000 after acquiring an additional 1,256,377 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Alkermes by 19.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company's stock valued at $123,467,000 after acquiring an additional 714,787 shares during the period. Institutional investors and hedge funds own 95.21% of the company's stock.
Analyst Ratings Changes
ALKS has been the subject of several recent research reports. Royal Bank Of Canada decreased their price target on shares of Alkermes from $47.00 to $45.00 and set an "outperform" rating for the company in a research report on Thursday, February 26th. Wolfe Research initiated coverage on shares of Alkermes in a research report on Monday, February 23rd. They issued an "outperform" rating and a $45.00 price target for the company. Wells Fargo & Company upped their price target on shares of Alkermes from $37.00 to $43.00 and gave the company an "overweight" rating in a research report on Thursday, February 26th. Zacks Research upgraded shares of Alkermes from a "strong sell" rating to a "hold" rating in a research report on Monday, April 27th. Finally, Truist Financial upgraded shares of Alkermes to a "strong-buy" rating in a research report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, Alkermes currently has an average rating of "Moderate Buy" and an average target price of $44.29.
Get Our Latest Stock Report on ALKS
About Alkermes
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
